Are we in the process of bottoming? Perhaps. The sector still cannot get the moves it deserves based on the fundamental news that has come the past couple of weeks. What will be most telling is when the macro fades and market rallies, does the sector outperform? In other words, have people noticed the good […]
May 7th Biotech Update
A good day for the sector despite a relatively bad day for the market. This is a rare occurrence for the sector to outperform (at least recently). One day does not make a trend but it was certainly encouraging to see the sector do well and if the market continues to slide it is unlikely […]
October 16 Biotech Update
Some interesting news that I want to focus on today. It seems that sentiment is finally starting to turn as the sector is rallying even though we have some less than bullish news events. Obviously every recent rally has been sold, so it will take some time before we can get comfort that the pattern […]
SRPT – FDA Says No To Sarepta AA
On Tuesday morning, Sarepta informed investors that in what appeared to be a change from its previous stance, the FDA was not supportive of the company’s planned Accelerated Approval filing for the DMD drug eteplirsen. Even more damaging, the agency not only called into question the legitimacy of dystrophin as a biomarker, but cast doubt […]
Biotech IPO’s hot in the first half of 2013
(jointly with Jason Chew and Juan Pedro Rodriguez Serrate) To say biotech IPOs have been hot seems like an understatement. The past year has been an open feeding frenzy for biotech companies looking to raise capital on the public markets. It would seem there is significant pent up pent up supply and demand for these […]
